NO20073615L - 3, 5-disubstituert og 3, 5, 7-trisubstituert-3H-oksazolo og 3H-tiazolo [4,5-d]pyrimidin-2-on forbindelser og prodrug derav - Google Patents

3, 5-disubstituert og 3, 5, 7-trisubstituert-3H-oksazolo og 3H-tiazolo [4,5-d]pyrimidin-2-on forbindelser og prodrug derav

Info

Publication number
NO20073615L
NO20073615L NO20073615A NO20073615A NO20073615L NO 20073615 L NO20073615 L NO 20073615L NO 20073615 A NO20073615 A NO 20073615A NO 20073615 A NO20073615 A NO 20073615A NO 20073615 L NO20073615 L NO 20073615L
Authority
NO
Norway
Prior art keywords
compounds
prodrugs
oxazolo
thiazolo
trisubstituted
Prior art date
Application number
NO20073615A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen E Webber
Erik J Rueden
Joseph R Lennox
Gregory J Haley
Alan Xin Xiang
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of NO20073615L publication Critical patent/NO20073615L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
NO20073615A 2004-12-17 2007-07-13 3, 5-disubstituert og 3, 5, 7-trisubstituert-3H-oksazolo og 3H-tiazolo [4,5-d]pyrimidin-2-on forbindelser og prodrug derav NO20073615L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63663304P 2004-12-17 2004-12-17
US63663404P 2004-12-17 2004-12-17
PCT/US2005/045589 WO2006066080A1 (fr) 2004-12-17 2005-12-16 Composes de 3h-oxazolo et 3h-thiazolo [4,5-d]pyrimidine-2-one disubstitues en 3, 5 et trisubstitues en 3, 5, 7 et promedicaments associes

Publications (1)

Publication Number Publication Date
NO20073615L true NO20073615L (no) 2007-09-12

Family

ID=36588217

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073615A NO20073615L (no) 2004-12-17 2007-07-13 3, 5-disubstituert og 3, 5, 7-trisubstituert-3H-oksazolo og 3H-tiazolo [4,5-d]pyrimidin-2-on forbindelser og prodrug derav

Country Status (28)

Country Link
US (4) US7560544B2 (fr)
EP (2) EP1824482B1 (fr)
JP (1) JP5303149B2 (fr)
KR (1) KR101320008B1 (fr)
CN (1) CN102504001B (fr)
AR (1) AR052995A1 (fr)
AU (1) AU2005316397B2 (fr)
BR (1) BRPI0518861B8 (fr)
CA (1) CA2589529C (fr)
DK (2) DK1824482T3 (fr)
EA (1) EA013594B1 (fr)
EG (1) EG25920A (fr)
ES (2) ES2525567T3 (fr)
GT (1) GT200500374A (fr)
IL (2) IL183512A (fr)
MX (1) MX2007007263A (fr)
MY (1) MY176938A (fr)
NO (1) NO20073615L (fr)
NZ (1) NZ555723A (fr)
PA (1) PA8657201A1 (fr)
PE (1) PE20060837A1 (fr)
PL (2) PL1824482T3 (fr)
PT (2) PT2561872E (fr)
SI (2) SI1824482T1 (fr)
TN (1) TNSN07208A1 (fr)
TW (1) TWI407956B (fr)
UY (1) UY29265A1 (fr)
WO (1) WO2006066080A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
DE602006015700D1 (de) * 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
KR101461604B1 (ko) * 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
WO2008011406A2 (fr) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Promédicaments à groupes fonctionnels carbonate et carbamate de thiazolo [4,5-d] pyrimidines
SI2076132T1 (sl) * 2006-10-17 2012-11-30 Anadys Pharmaceuticals Inc Sol p toulen sulfonske kisline s amino o acetil deoksi beta d ribofuranosil h tiazol d pirimidin on in metodami za njeno pripravo
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
WO2009026292A1 (fr) * 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Procédés de dosage pour le traitement de pathologies
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
WO2010082050A1 (fr) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
PH12012501216A1 (en) 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
WO2014121416A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014121417A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014121418A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
US9227718B2 (en) * 2013-06-07 2016-01-05 The Boeing Company Lower joints between outboard wing boxes and center wing sections of aircraft wing assemblies
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
JP2017531655A (ja) * 2014-10-11 2017-10-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染性疾患の処置に使用するための化合物
SG11201704512PA (en) * 2014-12-08 2017-07-28 Hoffmann La Roche 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
CA2979490C (fr) * 2015-03-16 2023-07-18 F. Hoffmann-La Roche Ag Traitement combine avec un agoniste de tlr7 et un inhibiteur d'assemblage de capside du virus de l'hepatite b
CN107743491B (zh) 2015-05-08 2020-08-21 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
JP6806709B2 (ja) * 2015-05-12 2021-01-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン
WO2017001307A1 (fr) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Nouvelle aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale
WO2017211791A1 (fr) 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Polythérapie à base d'un inhibiteur de hbsag et d'un agoniste de tlr7
CA3048768A1 (fr) 2017-01-06 2018-07-12 F. Hoffmann-La Roche Ag Procede de preparation de composes 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione a substitution en position 3
CA3101364A1 (fr) * 2018-05-25 2019-11-28 Primmune Therapeutics, Inc. Agonistes de tlr7
CN112534055A (zh) 2018-07-13 2021-03-19 豪夫迈·罗氏有限公司 用于调节rtel1表达的寡核苷酸
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
AU2020391487B2 (en) * 2019-11-26 2026-04-23 Primmune Therapeutics, Inc. TLR7 agonists
EP4081217A1 (fr) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Association pharmaceutique d'agents antiviraux ciblant le vhb et/ou un modulateur immunitaire pour le traitement du vhb
MX2022007908A (es) 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
US20240156795A1 (en) * 2020-11-24 2024-05-16 Lankenau Institute For Medical Research Methods and compositions for the treatment of drug resistant topical infections
WO2022197927A1 (fr) * 2021-03-18 2022-09-22 Lankenau Institute For Medical Research Méthodes et compositions pour le traitement d'infections topiques résistantes aux médicaments
WO2023288047A2 (fr) * 2021-07-15 2023-01-19 Alnylam Pharmaceuticals, Inc. Multiplexage ciblant des ligands par chimie clic au niveau du site anomérique de sucres
KR20240101580A9 (ko) 2021-11-11 2025-12-10 에프. 호프만-라 로슈 아게 Hbv 치료를 위한 약학 조합물

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4643992A (en) * 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4539205A (en) * 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4746651A (en) * 1983-11-01 1988-05-24 Scripps Clinic And Research Foundation Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives
US5166141A (en) * 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US5011828A (en) * 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8712745D0 (en) * 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5041542A (en) 1988-06-03 1991-08-20 Nucleic Acid Research Institute Substituted pyrimido[5,4-d]pyrimidine nucleosides
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9015914D0 (en) * 1990-07-19 1990-09-05 Wellcome Found Heterocyclic compounds
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
GB9105899D0 (en) 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU5165793A (en) 1992-10-01 1994-04-26 Mcneilab, Inc. Derivatives of 7,8-disubstituted guanosines
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5994321A (en) 1993-12-20 1999-11-30 Aronex Pharmaceuticals, Inc. Antiviral guanine analogs
US5446045A (en) 1993-12-20 1995-08-29 Revankar; Ganapathi R. Antiviral guanine analogs
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5970974A (en) 1995-03-14 1999-10-26 Siemens Aktiengesellschaft Dosating unit for an ultrasonic atomizer device
EP0814860B1 (fr) 1995-03-14 1999-11-03 Siemens Aktiengesellschaft Atomiseur a ultrasons pourvu d'une unite de dosage precis amovible
ES2232871T3 (es) * 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
BR9714349A (pt) * 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
IL129319A0 (en) 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
DE69817393T2 (de) * 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP2002510695A (ja) * 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
US6914068B2 (en) * 2001-07-12 2005-07-05 Basf Aktiengesellschaft Thiazolo[4,5-b]pyridines as fungicides
AP2004003069A0 (en) 2001-11-27 2004-06-30 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US20040063658A1 (en) * 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2004096233A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues d'un phosphonate nucleosidique
CA2566541C (fr) * 2004-06-07 2012-10-09 Anadys Pharmaceuticals, Inc. Nucleosides 3-beta-d-ribofuranosylthiazolo[4,5-d]pyrimidiniques et leurs utilisations

Also Published As

Publication number Publication date
CN102504001A (zh) 2012-06-20
PT2561872E (pt) 2014-12-18
IL220759A (en) 2015-07-30
WO2006066080A1 (fr) 2006-06-22
BRPI0518861A2 (pt) 2009-03-24
ES2525567T3 (es) 2014-12-26
DK2561872T3 (en) 2014-12-08
EP2561872B1 (fr) 2014-09-10
IL183512A (en) 2013-04-30
CA2589529C (fr) 2013-09-10
AU2005316397A1 (en) 2006-06-22
PL2561872T3 (pl) 2015-03-31
BRPI0518861B8 (pt) 2021-05-25
CN102504001B (zh) 2015-02-25
EP1824482B1 (fr) 2014-02-12
JP5303149B2 (ja) 2013-10-02
KR101320008B1 (ko) 2013-10-18
EA013594B1 (ru) 2010-06-30
TNSN07208A1 (en) 2008-11-21
SI2561872T1 (sl) 2015-02-27
CA2589529A1 (fr) 2006-06-22
HK1108377A1 (en) 2008-05-09
DK1824482T3 (en) 2014-03-24
PA8657201A1 (es) 2006-12-07
UY29265A1 (es) 2006-07-31
IL220759A0 (en) 2012-08-30
HK1175990A1 (en) 2013-07-19
PT1824482E (pt) 2014-05-13
US7560544B2 (en) 2009-07-14
MX2007007263A (es) 2007-08-14
EP2561872A1 (fr) 2013-02-27
IL183512A0 (en) 2007-09-20
EP1824482A4 (fr) 2009-08-26
SI1824482T1 (sl) 2014-06-30
KR20070107005A (ko) 2007-11-06
JP2008534437A (ja) 2008-08-28
TWI407956B (zh) 2013-09-11
NZ555723A (en) 2010-07-30
ES2459368T3 (es) 2014-05-09
BRPI0518861B1 (pt) 2021-03-09
EG25920A (en) 2012-10-15
EA200701296A1 (ru) 2007-12-28
US20130259831A1 (en) 2013-10-03
AR052995A1 (es) 2007-04-18
TW200635588A (en) 2006-10-16
US8883758B2 (en) 2014-11-11
MY176938A (en) 2020-08-27
US20110275589A1 (en) 2011-11-10
PE20060837A1 (es) 2006-09-02
US8097718B2 (en) 2012-01-17
EP1824482A1 (fr) 2007-08-29
US20060160830A1 (en) 2006-07-20
US20120121541A1 (en) 2012-05-17
AU2005316397B2 (en) 2012-02-02
PL1824482T3 (pl) 2014-07-31
GT200500374A (es) 2006-07-03

Similar Documents

Publication Publication Date Title
NO20073615L (no) 3, 5-disubstituert og 3, 5, 7-trisubstituert-3H-oksazolo og 3H-tiazolo [4,5-d]pyrimidin-2-on forbindelser og prodrug derav
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
NO20063787L (no) Terapeutiske preparater
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
WO2005069865A3 (fr) Derives de pyrrolopyrimidine et analogues et utilisation dans le traitement et la prevention de maladies
NO20061743L (no) Kinazolinderivater
WO2006113864A3 (fr) Composes d'oxindole et leurs utilisations comme agents therapeutiques
NO20073719L (no) Kjemiske forbindelser
WO2004062625A3 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
WO2005004803A3 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20082709L (no) Kjemiske forbindelser
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20081844L (no) Terapeutiske forbindelser
WO2007064932A3 (fr) Dérivés de pyrrolotriazine utiles pour traiter le cancer par inhibition de la kinase aurora
WO2005018545A3 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
WO2005051914A8 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
TW200611695A (en) Pyrrolopyridine derivatives
NO20070061L (no) 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
AU2003260436A1 (en) Pyrimidine compounds
NO20064974L (no) terapeutiske midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application